INSM — Insmed Income Statement
0.000.00%
Last trade - 00:00- $12.67bn
- $12.37bn
- $363.71m
Annual income statement for Insmed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 164 | 188 | 245 | 305 | 364 |
| Cost of Revenue | |||||
| Gross Profit | 125 | 144 | 190 | 240 | 278 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 430 | 581 | 703 | 1,015 | 1,242 |
| Operating Profit | -265 | -393 | -457 | -710 | -878 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -293 | -436 | -480 | -747 | -910 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -294 | -435 | -482 | -750 | -914 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -294 | -435 | -482 | -750 | -914 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -294 | -435 | -482 | -750 | -914 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.01 | -3.73 | -4.02 | -5.2 | -5.21 |